PitchBook-2024年二季度医疗技术公共报表和估值指南（英）-2024
EMERGING TECH RESEARCH PitchBook Data, Inc. Nizar Tarhuni Vice President, Institutional Research
报告摘要
EMERGING TECH RESEARCH PitchBook Data, Inc. Nizar Tarhuni Vice President, Institutional Research
报告信息
- 文件全名
- 《PitchBook-2024年二季度医疗技术公共报表和估值指南（英）-2024-9页.pdf》
- 适合读者
- 核心数据
- the remainder of the year compared to the years ahead. Consensus anticipates EPS growth from -3% up to 9% for the various
- expect double-digit EPS growth across the board and EPS growth above 15% for both the diagnostics and consumer health
- performing medtech stocks in the quarter, with gains of 18.4% and 17.8%, respectively. After initial market panic in 2023 about the
- Exact Sciences, and Eurofins all declining more than 20%. Illumina’s shares remain under pressure from the forced divestiture of
- 3.9% and 8.3%, respectively, indicating that investors have been recently rotating away from medtech and toward other sectors.
- 核心议题
常见问题
《PitchBook-2024年二季度医疗技术公共报表和估值指南（英）-2024》主要包含哪些内容?
EMERGING TECH RESEARCH PitchBook Data, Inc. Nizar Tarhuni Vice President, Institutional Research核心数据:the remainder of the year compared to the years ahead. Consensus anticipates EPS growth from -3% up to 9% for the various;expect double-digit EPS growth across the board and EPS growth above 15% for both the diagnostics and consumer health;performing medtech stocks in the quarter, with gains of 18.4% and 17.8%, respectively. After initial market panic in 2023 about the。
这份报告由哪家机构发布?
本报告由PitchBook发布,发布于 2024 年。
这份报告覆盖哪一年、篇幅多大?
覆盖 2024 年,全文约 9。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合战略规划、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了医疗等议题。
继续阅读
查看全部 →